NasdaqGS - Delayed Quote USD

Prothena Corporation plc (PRTA)

4.6600
+0.0700
+(1.53%)
At close: June 2 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
137,935
135,157
91,370
53,905
200,577
Operating Expense
276,549
289,718
282,406
185,462
128,602
Operating Income
-138,614
-154,561
-191,036
-131,557
71,975
Net Non Operating Interest Income Expense
22,999
25,816
31,014
6,349
42
Other Income Expense
-248
-185
-458
-397
-96
Pretax Income
-115,863
-128,930
-160,480
-125,605
71,921
Tax Provision
-5,597
-6,620
-13,452
-8,656
4,946
Net Income Common Stockholders
-110,266
-122,310
-147,028
-116,949
66,975
Diluted NI Available to Com Stockholders
-110,266
-122,310
-147,028
-116,949
66,975
Basic EPS
-2.05
-2.27
-2.76
-2.47
1.51
Diluted EPS
-2.05
-2.27
-2.76
-2.47
1.38
Basic Average Shares
53,800.2500
53,772
53,216
47,369
44,228
Diluted Average Shares
53,800.2500
53,772
53,216
47,369
48,464
Total Operating Income as Reported
-138,614
-154,561
-191,036
-131,557
71,975
Total Expenses
276,549
289,718
282,406
185,462
128,602
Net Income from Continuing & Discontinued Operation
-110,266
-122,310
-147,028
-116,949
66,975
Normalized Income
-110,089.9368
-122,134.4990
-146,608.3912
-116,579.3590
66,975
Interest Income
22,999
25,816
31,014
6,349
42
Interest Expense
0
--
--
--
--
Net Interest Income
22,999
25,816
31,014
6,349
42
EBIT
-138,614
-154,561
-191,036
-131,557
71,975
EBITDA
-137,713
-153,668
-190,108
-130,813
73,090
Reconciled Depreciation
901
893
928
744
1,115
Net Income from Continuing Operation Net Minority Interest
-110,266
-122,310
-147,028
-116,949
66,975
Total Unusual Items Excluding Goodwill
-185
-185
-458
-397
0
Total Unusual Items
-185
-185
-458
-397
0
Normalized EBITDA
-137,528
-153,483
-189,650
-130,416
73,090
Tax Rate for Calcs
0
0.0001
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
-8.9368
-9.4990
-38.3912
-27.3590
0
12/31/2021 - 12/18/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SVRA Savara Inc.
2.4000
+5.26%
 
RCKT Rocket Pharmaceuticals, Inc.
2.7700
+10.36%
 
ITOS iTeos Therapeutics, Inc.
10.01
-0.10%
 
BCAX Bicara Therapeutics Inc.
9.90
+7.03%
 
ARVN Arvinas, Inc.
7.33
+1.81%
 
IFRX InflaRx N.V.
0.8100
+0.93%
 
TSHA Taysha Gene Therapies, Inc.
2.7850
+2.77%
 
ORIC ORIC Pharmaceuticals, Inc.
8.47
+3.67%
 
MLTX MoonLake Immunotherapeutics
41.16
+5.51%
 
LXEO Lexeo Therapeutics, Inc.
2.7200
0.00%